


Process for the preparation of amino alcohols and derivatives thereof

The invention relates to a novel process for the preparation of (1R,4S)- or (1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene of the formulae




I




II

and/or of (1S,4R)- or (1R,4S)-amino alcohol derivatives of the general formulae




III



IV

and to novel microorganisms which are able to utilize a cyclopentene derivative of the general formula



VII

as sole nitrogen source, as sole carbon source or as sole carbon and nitrogen source.

The invention further relates to enzyme extracts and enzymes having N-acetylamino-alcohol hydrolase activity obtainable from these microorganisms.

(1R,4S)-1-Amino-4-(hydroxymethyl)-2-cyclopentene of the formula I is an important intermediate for the preparation of carbocyclic nucleosides such as, for example, Carbovir® (Campbell et al., J. Org. Chem. 1995, 60, 4602 - 4616).

Processes for the preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene are described by Campbell et al. (ibid) and by Park K. H. & Rapoport H. (J. Org. Chem. 1994, 59, 394 - 399).

The precursor used in these processes is either D-glucono-δ-lactone or D-serine, and about 15 synthesis

09992982-11401

stages are necessary to form (1R,4S)-N-tert-butoxycarbonyl-4-hydroxymethyl-2-cyclopenten, which is then deprotected to give (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene. These two processes are costly, elaborate and cannot be implemented industrially.

WO 93/17020 describes a process for the preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene, wherein (1R,4S)-4-amino-2-cyclopentene-1-carboxylic acid is reduced with lithium aluminium hydride to the desired product.

The disadvantage of this process is, on the one hand, that the double bond of the cyclopentene ring is also reduced, the lithium aluminium hydride is difficult to handle, and, on the other hand, that it is too costly.

Taylor, S. J. et al. (Tetrahedron: Asymmetry Vol. 4, No. 6, 1993, 1117 - 1128) describe a process for the preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene starting from (+)-2-azabicyclo[2.2.1]hept-5-en-3-one as precursor. In this case, the precursor is converted by means of microorganisms of the species *Pseudomonas solanacearum* or *Pseudomonas fluorescens* into (1R,4S)-2-azabicyclo[2.2.1]hept-5-en-3-one, which is then converted with di-tert-butyl dicarbonate into (1R,4S)-N-tert-butoxycarbonyl-2-azabicyclo[2.2.1]hept-5-en-3-one, which is reduced with sodium borohydride and trifluoroacetic acid to the desired product. This process is much too costly.

In addition, Martinez et al. (J. Org. Chem. 1996, 61, 7963 - 7966) describe a 10-stage synthesis of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene starting from diethyl dialkylmalonate. This process also has the disadvantage that it is elaborate and cannot be implemented industrially.

It was an object of the present invention to provide a simple process for the preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene.


This object is achieved with the microorganisms of the invention according to Claim 1, and enzyme extracts therefrom, with the enzymes of the invention

09992982 111401

according to Claim 4 and with the process of the invention according to Claim 7.

The microorganisms of the invention can be isolated from soil samples, sludge or waste water with the assistance of conventional microbiological techniques.

The microorganisms are isolated according to the invention by cultivating them in a nutrient medium containing one or more cyclopentene derivatives of the general formula



in which R¹ denotes C₁-C₄-alkyl, C₁-C₄-alkoxy, aryl or aryloxy,

- as sole carbon and nitrogen source
 - as sole nitrogen source with a suitable carbon source or
 - as sole carbon source with a suitable nitrogen source,
- in a conventional way.

It is possible to use as C₁-C₄-alkyl for example methyl, ethyl, propyl, isopropyl or butyl. It is possible to use as C₁-C₄-alkoxy for example methoxy, ethoxy, propoxy, isopropoxy, butoxy or tert-butoxy. It is possible to use as aryl for example phenyl or benzyl. Benzyl is preferably used. It is possible to use as aryloxy for example benzyloxy or phenoxy. Accordingly, the following examples are suitable as cyclopentene derivative of the general formula VII:

1-acetylamino-4-hydroxymethyl-2-cyclopentene, 1-butyrylamino-4-hydroxymethyl-2-cyclopentene or 1-phenylacetylamino-4-hydroxymethyl-2-cyclopentene.

It is expedient to select from the culture obtained by cultivation those which utilize the (1R,4S) isomer of the cyclopentene derivative of the formula VII as sole nitrogen source, as sole carbon source or as sole carbon and nitrogen source.

The microorganisms can use as suitable nitrogen

source, for example, ammonium, nitrates, amino acids or
ur as as substrate for growth. The microorganisms can use
as suitable carbon source, for example, sugars, sugar
alcohols, C₂-C₄-carboxylic acids or amino acids as
5 substrate for growth. Hexoses such as glucose or pentoses
can be used as sugars. Glycerol, for example, can be used
as sugar alcohol. Acetic acid or propionic acid can be
used, for example, as C₂-C₄-carboxylic acids. Leucine,
alanine, asparagine can be used, for example, as amino
10 acids.

The selection medium and culture medium which can
be used are those conventional among those skilled in the
art, such as, for example, the one described in Table 1
or a complete medium (medium containing yeast extract),
15 preferably using the one described in Table 1.

During the culturing and selection, the active
enzymes of the microorganisms are expediently induced.
The cyclopentene derivatives of the general formula VII
can be used as enzyme inducer.

20 The culturing and selection normally takes place
at a temperature from 20°C to 40°C, preferably from 30°C
to 38°C and at a pH between 5.5 and 8.0, preferably
between 6.8 and 7.8.

Preferred microorganisms are those of the genus
25 Rhodococcus, Gordona, Arthrobacter, Alcaligenes, Agro-
bacterium/Rhizobium, Bacillus, Pseudomonas or
Alcaligenes/Bordetella, in particular of the species
Rhodococcus erythropolis CB 101 (DSM 10686),
Alcaligenes/Bordetella FB 188 (DSM 11172), Arthrobacter
30 sp. HSZ 5 (DSM 10328), Rhodococcus sp. FB 387 (DSM
11291), Alcaligenes xylosoxydans ssp. denitrificans
HSZ 17 (DSM 10329), Agrobacterium/Rhizobium HSZ 30,
Bacillus simplex K2, Pseudomonas putida K32, or Gordona
sp. CB 100 (DSM 10687) and their functionally equivalent
35 variants and mutants. Deposition in accordance with the
Budapest Treaty at the Deutsche Sammlung von Mikro-
organismen und Zellkulturen GmbH (DSMZ), Mascheroderweg
1b, D-38124 Braunschweig, took place on 20.05.1996 for
the microorganisms DSM 10686 and 10687, on 6.11.1995 for

T04TTT 2862660

the microorganisms DSM 10328 and DSM 10329, on 8.10.1996 for the microorganism DSM 11291 and on 20.09.1996 for the microorganism DSM 11172.

- "Functionally equivalent variants and mutants" mean microorganisms having essentially the same properties and functions as the original microorganisms. Variants and mutants of this type can be produced by chance, for example by UV radiation.

10 Taxonomic description of *Alcaligenes/Bordetella* FB 188 (DSM 11172)

	Cell form	rods
	Width μm	0.5 - 0.6
	Length μm	1.0 - 2.5
	Motility	+
15	Flagellation	peritrichous
	Gram reaction	-
	Lysis by 3% KOH	+
	Aminopeptidase (Cerny)	+
	Spores	-
20	Oxidase	+
	Catalase	+
	ADH (alcohol dehydrogenase)	-
	NO ₂ from NO ₃	-
	Denitrification	-
25	Urease	-
	Hydrolysis of gelatin	-
	Acid from (OF test):	
	Glucose	-
	Fructose	-
30	Arabinose	-
	Adipate	+
	Caprate	+
	Citrate	+
	Malate	+
35	Mannitol	-

09992982-111401

Taxonomic description of *Rhodococcus erythropolis* CB 101 (DSM 106 86)

1. Morphology and color of the colonies: short branched hyphae which, when old, disintegrate into rods and cocci, colonies glistening and partly confluent, beige with pink tinge, RAL 1001;
2. Diagnosed amino acid of the peptidoglycan: meso-diaminopimelic acid;
3. Mycolic acids: *Rhodococcus* mycolic acids; determination of the mycolic acid chain length (C_{32} - C_{44}) and comparison of the data with the entries in the DSM mycolic acid data bank revealed very great similarity with the patterns of the *Rhodococcus erythropolis* strains (similarity 0.588).
4. Fatty acid pattern: unbranched, saturated and unsaturated fatty acids plus tuberculostearic acid.
5. On partial sequencing of the 16S rDNA of the strain, a high level of agreement (100%) was found with the sequences of the specific regions of *Rhodococcus erythropolis*.

The identification result is unambiguous because three mutually independent methods (mycolic acids, fatty acids, 16S rDNA) have assigned the strain to the species *Rhodococcus erythropolis*.

25 Taxonomic description of *Gordona* sp. CB 100 (DSM 10687)

1. Morphology and color of the colonies: short branched hyphae which, when old, disintegrate into rods and cocci, colonies pale orange, (RAL 2008);
2. Diagnosed amino acid of the peptidoglycan: meso-diaminopimelic acid;
3. Menaquinone pattern: MK-9 (H_2) 100%;
4. Mycolic acids: *Gordona* mycolic acids; the mycolic acid chain length (C_{50} - C_{60}) was determined by high temperature gas chromatography. This pattern corresponds to the pattern found in representative of the genus *Gordona*.
5. Fatty acid pattern: unbranched, saturated and unsatu-

rated fatty acids plus tuberculostearic acid.

6. On partial sequencing of the 16S rDNA of the strain, only a relatively low agreement of 98.8% could be found with the sequences of the specific regions of *Gordona rubropertincta*.

On the basis of the available results (menaquinones, mycolic acids, fatty acids, 16S rDNA), although the isolate can be unambiguously assigned to the genus *Gordona* it is not possible on the basis of the results to make an assignment to a known *Gordona* species. It is therefore to be assumed that the strain DSM 10687 is a new and previously undescribed species of the genus *Gordona*.

Taxonomic description of *Alcaligenes xylosoxydans* ssp. *denitrificans* HSZ 17 (DSM 10329)

Properties of the strain

	Cell form	rods
	Width μm	0.5-0.6
	Length μm	1.5-3.0
20	Motility	+
	Flagellation	peritrichous
	Gram reaction	-
	Lysis by 3% KOH	+
	Aminopeptidase (Cerny)	+
25	Spores	-
	Oxidase	+
	Catalase	+
	Anaerobic growth	-
	ADH (alcohol dehydrogenase)	+
30	NO ₂ from NO ₃	+
	Denitrification	+
	Urease	-
	Hydrolysis of	
	Gelatin	-
35	Tween 80	-
	Acid from (OF test):	
	Glucose aerobic	-
	Xylose 80	-

0902082-11401

Substrate utilization

	Glucose	-
	Fructose	-
	Arabinose	-
5	Citrate	+
	Malate	+
	Mannitol	-

Taxonomic description of *Arthrobacter* sp. HSZ5 (DSM 10328)

10	Characterization:	Gram-positive irregular rods with a pronounced rod-cocci growth cycle; strictly aerobic; no acid or gas formation from glucose.
15	Motility	-
	Spores	-
	Catalase	+
	meso-Diaminopimelic acid in the cell wall:	no
20	Peptidoglycan type:	A3 α , L-Lys-L-Ser-L-Thr-L-Ala
	16S rDNA sequence similarity:	The highest values found on sequencing the region with the greatest variability were 98.2% with <i>Arthrobacter pascens</i> , <i>A. ramosus</i> and <i>A. oxydans</i>
25		

Taxonomic description of *Agrobacterium/Rhizobium* HSZ30

	Cell form	pleomorphic rods
	Width [μ m]	0.6-1.0
30	Length [μ m]	1.5-3.0
	Gram reaction	-
	Lysis by 3% KOH	+
	Aminopeptidase	+
	Spores	-
35	Oxidase	+
	Catalase	+
	Motility	+

T04T1T - 2862660

	Anaerobic growth	-
	Nitrite from nitrate	-
	Denitrification	-
	Urease	+
5	Hydrolysis of gelatin	-
	Acid from:	
	L-Arabinose	+
	Galactose	-
	Melezitose	-
10	Fucose	+
	Arabitol	-
	Mannitol	-
	Erythritol	-
	Alkalinization of litmus milk	+
15	Ketolactose	-

Partial sequencing of the 16S rDNA revealed comparably large similarities of about 96% with representatives of the genera *Agrobacterium* and *Rhizobium*. Unambiguous assignment to a species described within these genera is not possible.

20 Taxonomic description of *Bacillus simplex* K2

	Cell form	rods
	Width [μ m]	0.8-1.0
	Length [μ m]	3.0-5.0
25	Spores	-
	Ellipsoidal	-
	Circular	-
	Sporangium	-
	Catalase	+
30	Anaerobic growth	-
	VP reaction	n.g.
	Maximum temperature	
	Growth positive at °C	40
	Growth negative at °C	45
35	Growth in medium pH 5.7	-
	NaCl 2%	+
	5%	-
	7%	-

09992982-111401

	10%	-
	Lysozyme medium	+
	Acid from (ASS)	
	D-Glucos	+
5	L-Arabinose	+
	D-Xylose	-
	D-Mannitol	+
	D-Fructose	+
	Gas from fructose	-
10	Lecithinase	-
	Hydrolysis of	
	Starch	+
	Gelatin	+
	Casein	-
15	Tween 80	+
	Aesculin	-
	Utilization of	
	Citrate	+
	Propionate	-
20	Nitrite from nitrate	+
	Indole	-
	Phenylalanine deaminase	-
	Arginine dihydrolase	-

25 Analysis of the cellular fatty acids yielded confirmation of the assignment to the genus *Bacillus*.

Partial sequencing of the 16S rDNA revealed a similarity of 100% with *Bacillus simplex*.

Taxonomic description of *Pseudomonas putida* K32

	Cell form	rods
30	Width [μ m]	0.8-0.9
	Length [μ m]	1.5-4.0
	Motility	+
	Flagellation	polar >1
	Gram reaction	-
35	Lysis by 3% KOH	+
	Aminop ptidas	+
	Spores	-
	Oxidas	+

09992982-11401

	Catalase	+
	Anaerobic growth	-
	Pigments	
	fluorescent	+
5	Pyocyanin	-
	ADH	+
	Nitrite from nitrate	-
	Denitrification	-
	Urease	-
10	Hydrolysis of gelatin	-
	Substrate utilization	
	Adipate	-
	Citrate	+
	Malate	+
15	D-Mandelate	+
	Phenylacetate	+
	D-Tartrate	-
	D-Glucose	+
	Trehalose	-
20	Mannitol	-
	Benzoylformate	-
	Propylene glycol	+
	Butylamine	+
	Benzylamine	+
25	Tryptamine	-
	Acetamide	+
	Hippurate	+

The profile of cellular fatty acids is typical of *Pseudomonas putida*.

- 30 Partial sequencing of the 16S rDNA revealed similarities of about 98% with *Pseudomonas mendocina* and *Pseudomonas alcaligenes*. The similarity with *Pseudomonas putida* was 97.4%.

35 Taxonomic description of *Rhodococcus* sp. FB 387 (DSM 11291)

1. Morphology and colour of the colonies: short branched hyphae which, when old, disintegrate to rods and

09992982-111401

cocci, colonies matt, pale red-orange RAL 2008;

2. Diagnosed amino acid of the peptidoglycan: meso-diaminopimelic acid;

3. Mycolic acids: Rhodococcus mycolic acids;

5 Determination of the mycolic acid chain length (C_{32} - C_{44}) and comparison of the data with the entries in the DSMZ mycolic acid data bank revealed only very small similarity with the patterns of Rhodococcus ruber strains (similarity 0.019). This correlation factor is too low to be used for species identification.

10 4. Fatty acid pattern: unbranched, saturated and unsaturated fatty acids plus tuberculostearic acid.

This fatty acid pattern is diagnostic for all representatives of the genus Rhodococcus and its close relatives such as Mycobacterium, Nocardia and Gordona. An attempt was made by including the qualitative and quantitative differences in the fatty acid pattern to carry out a differentiation to the species level. Numerical methods were used to compare the fatty acid pattern of Rhodococcus sp. FB 387 with the entries in the data bank. It was not possible with this method either to assign Rhodococcus sp. FB 387, because of the small similarity (0.063), to any described Rhodococcus species.

20 5. On partial sequencing of the 16S rDNA of the strain, 96-818 was assigned to Rhodococcus opacus with a correlation of 97.9%. This sequence agreement is far below that of 99.5% required for unambiguous species assignment in this taxon.

30 On the basis of the available results, it can be assumed that the strain Rhodococcus sp. FB 387 is a new and not previously described Rhodococcus species.

The enzymes of the invention, the N-acetylalcohol hydrolases which are able to hydrolyse cyclopentene derivatives of the above formula VII, can be obtained, for example, by disruption of the microorganism cells of the invention in a way conventional for the skilled person. It is possible to use for this for

099282-11401

example the ultrasound or French press method. These enzymes can be obtained for example from *Rhodococcus erythropolis* CB 101 (DSM 10686) microorganisms. Enzymes obtainable from the microorganisms of the invention, especially *Rhodococcus erythropolis* CB 101 (DSM 10686), preferably have the following properties:

- a) a pH optimum of $\text{pH } 7.0 \pm 1.0$;
- b) a temperature optimum between 25° and 30°C at a pH of 7.0; and
- 10 c) a K_m for the substrate 1-acetylamino-hydroxymethyl-2-cyclopentene of $22.5 \text{ mM} \pm 7.5 \text{ mM}$ (30°C , 100 mM phosphate buffer, pH 7.0).

Sequence analysis of an enzyme obtainable from *Rhodococcus erythropolis* CB 101 (DSM 10686) further revealed:


- 15 d) an N-terminal amino acid sequence of Thr-Glu-Gln-Asn-Leu-His-Trp-Leu-Ser-Ala-Thr-Glu-Met-Ala-Ala-Ser-Val-Ala-Ser-Asn;

and a molecular weight determination revealed:

- 20 e) a molecular weight of 50 kD determined by SDS-PAGE.

Enzymes like those obtainable from the microorganisms of the invention, for example *Rhodococcus erythropolis* CB 101 (DSM 10686), hydrolyse, for example, in particular 1-acetylamino-4-hydroxymethyl-2-cyclopentene, 1-butyrylamino-4-hydroxymethyl-2-cyclopentene, 1-propionylamino-4-hydroxymethyl-2-cyclopentene and 1-isobutyrylamino-4-hydroxymethyl-2-cyclopentene.

The process of the invention for the preparation of (1R,4S) - or (1S,4R) - 1-amino-4-(hydroxymethyl)-2-cyclopentane of the formulae




I




II

and/or of (1S,4R)- or (1R,4S)-amino alcohol derivatives of the general formulae




III




IV

in which R¹ has the stated meaning, can be carried out for example by, in a first stage, acylating (±)-2-azabicyclo[2.2.1]hept-5-en-3-one of the formula



V

to give a (±)-2-azabicyclo[2.2.1]hept-5-en-3-one derivative of the general formula




VI

in which R¹ has the stated meaning.


The precursor (±)-2-azabicyclo[2.2.1]hept-5-en-3-one can be prepared as disclosed in EP-B 0 508 352.

The acylation can be carried out with a carbonyl halide of the general formula



VIII ,

in which X denotes a halogen atom, and R¹ has the stated meaning, or with a carboxylic anhydride of the general formula



IX ,

in which R¹ has the stated meaning.

F, Cl, Br or I can be used as halogen atom X. Cl or F is preferably used.


Examples of carbonyl halides are: acetyl chloride, chloroacetyl chloride, butyryl chloride, isobutyryl chloride, phenylacetyl chloride, benzyl chloroformate (Cbz-Cl), propionyl chloride, benzoyl chloride, allyl chloroformate or tert-butyl fluoroformate. Examples of carboxylic anhydrides are: di-tert-butyl dicarbonate, butyric anhydride, acetic anhydride or propionic anhydride.

The acylation can be carried out without solvent or with an aprotic solvent.

The acylation is expediently carried out in an aprotic solvent. Examples of suitable aprotic solvents are pyridine, acetonitrile, dimethylformamide, tetrahydrofuran, toluene, methylene chloride, N-methylpyrrolidone or mixtures thereof. The solvent preferably used is pyridine or acetonitrile, in particular a mixture of pyridine and acetonitrile.

The acylation is expediently carried out at a temperature from -80 to 50°C, preferably from 0 to 25°C.

In a second stage of the process, the (±)-2-azabicyclo[2.2.1]hept-5-en-3-one derivative of the formula VI can be reduced to give a cyclopentene derivative of the general formula



VII

in which R¹ has the stated meaning.


The reduction is expediently carried out with an alkali metal borohydride or alkaline earth metal borohydride, with an alkali metal aluminium hydride or alkaline earth metal aluminium hydride or with Vitride (sodium bis(2-methoxyethoxy)aluminium hydride). Sodium or potassium aluminium hydride can be used as alkali metal aluminium hydride. Sodium or potassium borohydride can be used as alkali metal borohydride. Calcium borohydride can

be used as alkaline earth metal borohydride.


The reduction is expediently carried out in a protic solvent. Protic solvents which can be used are lower aliphatic alcohols such as methanol, thanol, propanol, isopropanol, butanol, isobutanol, sec-butanol, tert-butanol, or water, or mixtures thereof.

The reduction is expediently carried out at a temperature from -40 to 40°C, preferably from 0 to 20°C.

The conversion of the cyclopentene derivative of the general formula VII into the (1R,4S)- or (1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene of the formulae



I




II

is carried out according to the invention either by means of microorganisms or enzyme extracts therefrom, by means of penicillin G acylases or by means of enzymes having N-acetylamino-alcohol hydrolase activity. This biotransformation results not only in the (1R,4S)- or (1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene of formula I or II, which is isolated where appropriate, but also in the (1S,4R)- or (1R,4S)-amino alcohol derivative of the general formulae



III



IV

in which R¹ has the stated meaning. The latter can likewise be isolated where appropriate.

All microorganisms which utilize a cyclopentene derivative of the general formula VII as sole nitrogen source, as sole carbon source or as sole carbon and nitrogen source are suitable. The biotransformation is expediently carried out with microorganisms which utilize the (1R,4S) isomer of the cyclopentene derivative as sole carbon source, as sole carbon and nitrogen source or as sole nitrogen source.

The biotransformation is preferably carried out

by means of microorganisms of the genus *Alcaligenes*/
Bordetella, *Rhodococcus*, *Arthrobacter*, *Alcaligenes*,
Agrobacterium/*Rhizobium*, *Bacillus*, *Pseudomonas* or
Gordona, in particular of the species *Algaligenes*/
5 *Bordetella* FB 188 (DSM 11172), *Rhodococcus erythropolis*
CB 101 (DSM 10686), *Arthrobacter* sp. HSZ 5 (DSM 10328),
Rhodococcus sp FP 387 (DSM 11291), *Alcaligenes xylos-*
oxydans ssp. *denitrificans* HSZ 17 (DSM 10329), *Agro-*
bacterium/*Rhizobium* HSZ 30, *Bacillus simplex* K2,
10 *Pseudomonas putida* K32, or *Gordona* sp. (DSM 19687), and
with the functional equivalent variants and mutants
thereof. These microorganisms are, as already described,
deposited in accordance with the Budapest Treaty.

The microorganism species very particularly
15 suitable for the process are *Alcaligenes*/*Bordetella* FB
188 (DSM 11172), *Rhodococcus erythropolis* CB 101 (DSM
10686) and *Gordona* sp. CB 100 (DSM 10687).

The biotransformation can be carried out, after
conventional initial cultivation of these microorganisms,
20 with quiescent cells (non-growing cells no longer
requiring a carbon and energy source) or with growing
cells. The biotransformation is preferably carried out
with quiescent cells.

The enzymes according to the invention which are
25 suitable for the process, the N-acetylamino-alcohol
hydrolases, can be obtained by the methods described
above and have the properties already described above.

Suitable penicillin G acylases are obtained from
many microorganisms such as, for example, bacteria or
30 actinomycetes, specifically from the following micro-
organisms: *Escherichia coli* ATCC 9637, *Bacillus mega-*
terium, *Streptomyces lavendulae* ATCC 13664, *Nocardia* sp.
ATCC 13635, *Providencia rettgeri* ATCC 9918, *Arthrobacter*
viscosus ATCC 15294, *Rhodococcus fascians* ATCC 12975,
35 *Streptomyces phaeochromogenes* ATCC 21289, *Achromobacter*
ATCC 23584 and *Micrococcus roseus* ATCC 416. Penicillin G
acylases which can be bought are used in particular, such
as penicillin G acylase EC 3.5.1.11 from *E.coli* (Boeh-
ringer Mannheim) or from *Bacillus megaterium*.

09992982.11401
FOI# 2862660

Immobilized penicillin G acylases are used in a preferred embodiment.

The biotransformation can be carried out in media usual in the art, such as, for example, in low-molarity phosphate, citrate or Hepes buffer, in water, in complete media such as, for example, Nutrient Yeast Broth (NYB) or in that described in the table. The biotransformation is preferably carried out in the medium shown in Table 1 or in low-molarity phosphate buffer.

The biotransformation is expediently carried out with a single or continuous addition of the cyclopentene derivative (formula VII) so that the concentration does not exceed 10% by weight, preferably 2% by weight.

The pH during the biotransformation can be in a range from 5 to 9, preferably from 6 to 8. The biotransformation is expediently carried out at a temperature from 20 to 40°C, preferably from 25 to 30°C.

If the (1S,4R)-1-amino-4-(hydroxymethyl)-2-cyclopentene is formed during the biotransformation, this can be converted into the (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene by acid hydrolysis, for example with hydrochloric acid.

Examples:

Example 1

Preparation of (±)-2-acetyl-2-azabicyclo[2.2.1]hept-5-en-3-one

100 g of (±)-2-azabicyclo[2.2.1]hept-5-en-3-one were dissolved in acetonitrile (800 ml) and pyridine (161.26 ml) under nitrogen. At 12°C, 104.5 g of acetyl chloride were added dropwise over the course of 2 hours. The mixture was then stirred at room temperature for 4.5 hours. 800 ml of water were added to the mixture, and the acetonitrile was evaporated off in vacuo. The aqueous phase was extracted 3 times with 400 ml of ethyl acetate. The combined org. phases were washed with 1N HCl (400 ml), water (400 ml), saturated NaCl (400 ml), dried with magnesium sulphate and completely evaporated. The

09992982-11401

residue was taken up in methylene chloride and filtered through silica g l. The filtrate was concentrated and the product was purified by distillation. 107.76 g of product were obtained as a clear liquid. The yield was 71%.

5 Boiling point (0.07 torr) : 51°C

¹H-NMR (CDCl₃): δ [ppm] 2.25 (AB syst., 2H);
400 MHz 2.8 (s, 3H);
3.42 (m, 1H);
5.30 (m, 1H);
10 6.89 (m, 1H);
6.92 (m, 1H);

Example 2

Preparation of (±)-2-butyryl-2-azabicyclo[2.2.1]hept-5-en-3-one

15 100.3 g of (±)-2-azabicyclo[2.2.1]hept-5-en-3-one
were dissolved in acetonitrile (720 ml) and pyridine
(142 ml) under nitrogen. At 12°C, 141.8 g of butyryl
chloride were added dropwise over the course of 1 hour.
The reaction was then stirred at room temperature for 3
20 hours. 720 ml of water were added to the mixture. The
acetonitrile was evaporated off in vacuo, and the aqueous
phase was extracted 3 times with ethyl acetate (300 ml).
The combined org. phases were washed with 1N HCl (350
ml), saturated NaCl (400 ml) and water (500 ml), dried
25 with magnesium sulphate and completely evaporated. The
product was purified by distillation. 107.76 g of product
were obtained as a clear liquid. The yield was 85%.

Boiling point (0.05 torr) : 70°C

¹H-NMR (CDCl₃): δ [ppm] 0.98 (t, J=8.5 Hz, 3H);
30 400 MHz 1.58-1.65 (2H);
2.23 (AB syst., 2H);
2.82-2.90 (2H);
3.42 (m, 1H);
5.30 (m, 1H);
35 6.62 (m, 1H);
6.90 (m, 1H).

09992982 111401
104777 2862660

Example 3**Preparation of (+)-2-phenylacetyl-2-azabicyclo[2.2.1]-hept-5-en-3-one**

33.4 g of (+)-2-azabicyclo[2.2.1]hept-5-en-3-one
5 were dissolved in acetonitrile (240 ml) and pyridine
(48.3 ml) under nitrogen. At 12°C, 68.6 g of phenylacetyl
chloride were added dropwise over the course of 30
minutes. The mixture was then stirred at room temperature
for 3.5 hours. 240 ml of water were added to the mixture.
10 The acetonitrile was evaporated off in vacuo, and the
aqueous phase was extracted 3 times with ethyl acetate
(150 ml). The combined org. phases were washed with 1N
HCl (150 ml), saturated NaCl (150 ml) and water (150 ml),
dried with magnesium sulphate and completely evaporated.
15 The crude product was filtered through silica gel
(hexane:ethyl acetate = 1:1). 68.34 g of the crude
product were obtained as a yellow oil.

Example 4**Preparation of (+)-2-propionyl-2-azabicyclo[2.2.1]hept-5-en-3-one**

47 g of (+)-2-azabicyclo[2.2.1]hept-5-en-3-one
were dissolved in acetonitrile (325 ml) and pyridine
(41 ml) under nitrogen. At 12°C, 43.9 g of propionyl
chloride were added dropwise over the course of 1 h. The
25 reaction was then stirred at room temperature for 5 h.
145 ml of water were added to the mixture, and the aceto-
nitrile was evaporated off in vacuo. The aqueous phase
was extracted 3 times with 115 ml of ethyl acetate. The
combined organic phases were washed with 1N HCl (140 ml),
30 saturated NaHCO₃ (40 ml) and NaCl (40 ml) solutions,
dried with sodium sulphate and completely evaporated. The
residue was purified by distillation. 55.8 g of title
compound were obtained and solidified on leaving to
stand. The yield was 81.6%.

35 Boiling point 2.8 mbar 75-80°C

Melting point: 54-56°C

¹H-NMR (DMSO-d₆): δ [ppm] 0.95 (t, 3H);
400 MHz 2.10 (quart., 1H);

09992982-11401

2.28 (quart., 1H);
2.64 (m, 2H);
3.42 (s, 1H);
5.16 (s, 1H);
6.78 (m, 1H);
6.96 (m, 1H).

Example 5

Preparation of (+)-2-isobutyryl-2-azabicyclo[2.2.1]hept-5-en-3-one

45.1 g of (+)-2-azabicyclo[2.2.1]hept-5-en-3-one were dissolved in acetonitrile (310 ml) and pyridine (39 ml) under nitrogen. At 10°C, 54.1 g of isobutyryl chloride were added dropwise over the course of 1 h. The reaction was then stirred at room temperature for 5 h. 140 ml of water were added to the mixture, and the acetonitrile was evaporated off in vacuo. The aqueous phase was extracted with 4x 120 ml of ethyl acetate. The combined organic phases were washed with 1N HCl (50 ml), saturated NaHCO₃ (50 ml) and NaCl (50 ml) solutions, dried with sodium sulphate and completely evaporated. The residue was boiled under reflux in n-hexane (240 ml) with active charcoal. After filtration of the active charcoal, the filtrate was cooled to 0°C and the title compound was filtered. 54.5 g of product were obtained. The yield was 76%.

Melting point: 41 - 42°C

¹H-NMR (DMSO-d₆): δ [ppm]
400 MHz
0.92 (d, 3H);
1.06 (d, 3H);
2.10 (m, 1H);
2.28 (m, 1H);
3.40 (m, 2H);
5.16 (s, 1H);
6.78 (m, 1H);
7.92 (m, 1H).

Example 6

Preparation of (+)-2-chloroacetyl-2-azabicyclo[2.2.1]hept-5-en-3-one

10.1 g of (+)-2-azabicyclo[2.2.1]hept-5-en-3-one

09992982-11401

were dissolved in a mixture of dichloromethane (10 ml), pyridine (8.4 ml) and 0.22 g of 4-N,N-dimethylamino-pyridine at 10°C under nitrogen. 13.5 g of chloroacetyl chloride were added dropwise over the course of 1 h. The temperature rose to 44°C. The mixture was stirred for a further 2 h at room temperature. 100 ml of water were added to the solution. After phase separation, the aqueous phase was extracted with 100 ml of dichloromethane. The combined organic phases were dried with sodium sulphate and completely evaporated. The residue was boiled in 100 ml of diisopropyl ether under reflux in the presence of 1 g of active charcoal for 10 minutes. After hot filtration, the filtrate was cooled to room temperature, and the solid was filtered and dried. 10.35 g of title compound were obtained. The yield was 60%.

Melting point: 86 - 88°C

¹H-NMR (CDCl₃): δ [ppm] 2.28 (d, 1H);
400 MHz 2.40 (d, 1H);
20 3.48 (s, 1H);
 4.56 (d, 2H);
 5.30 (s, 1H);
 6.70 (d, 1H);
 6.94 (m, 1H).

25 Example 7

Preparation of (+)-1-acetylamino-4-hydroxymethyl-2-cyclopentene

79.56 g of (+)-2-acetyl-2-azabicyclo[2.2.1]hept-5-en-3-one were dissolved in ethanol (450 ml) under nitrogen and cooled to -10°C. 19.8 g of sodium borohydride were added in portions over the course of 45 minutes.

The reaction was stirred at 0°C for 3 hours and then the pH was adjusted to 1.8 with conc. sulphuric acid. Ethyl acetate (200 ml) was added to this mixture, and the solids were filtered off. It was then completely vaporated. The residue was taken up in water, washed with methylene chloride and completely evaporated. The

crude product was purified by a silica gel filtration using ethyl acetate/methanol 5:1 as solvent. The filtrate was concentrated. 51.83 g of product were obtained as a white solid. The yield was 64% based on 2-acetyl-2-azabicyclo[2.2.1]hept-5-en-3-one employed.

Melting point 91 - 93°C

¹ H-NMR (DMSO-d ₆): δ [ppm]	1.18 (m, 1H);
400 MHz	1.78 (s, 3H);
	2.29 (m, 1H);
	2.66 (m, 1H);
	3.35 (s, 2H);
	4.58 (s, 1H);
	4.72 (m, 1H);
	5.61 (d, 1H);
	5.85 (d, 1H);
	7.83 (d, 1H).

Example 8

Preparation of (±)-1-butyrylamino-4-hydroxymethyl-2-cyclopentene

73.87 g of (±)-2-butyryl-2-azabicyclo[2.2.1]hept-5-en-3-one were dissolved in ethanol (400 ml) under nitrogen and cooled to -10°C. 15.68 g of sodium borohydride were added in portions over the course of 45 minutes. The reaction was stirred at 0°C for 3 hours and then the pH was adjusted to 1.5 with conc. sulphuric acid. Ethyl acetate (200 ml) was added to this mixture, and the solids were filtered off. It was then completely evaporated. The residue was taken up in water, washed with methylene chloride, evaporated and dried under high vacuum. 60.55 g of product were obtained. The yield was 80% based on (±)-2-butyryl-2-azabicyclo[2.2.1]hept-5-en-3-one employed.

Melting point 71 - 72°C

¹ H-NMR (CDCl ₃): δ [ppm]	0.98 (t, J=8.5 Hz, 3H);
400 MHz	1.40 - 1.50 (1H);

1.58 - 1.68 (2H);
2.10 - 2.18 (2H);
2.42 - 2.55 (1H);
2.85 (m, 1H);
3.62 (AB syst., 2H);
4.98 (m, 1H);
5.78 - 5.82 (2H);
6.38 (m, 1H).

Example 9

10 Preparation of (+)-1-phenylacetyl-amino-4-hydroxymethyl-2-cyclopentene

67 g of crude (+)-2-phenylacetyl-2-azabicyclo-[2.2.1]hept-5-en-3-one were dissolved in ethanol (450 ml) under nitrogen and cooled to -10°C. 13.2 g of sodium borohydride were added in portions over the course of 1 hour. The reaction was stirred at room temperature for 3.5 hours and then the pH was adjusted to 3.8 with conc. sulphuric acid. The mixture was completely evaporated. The residue was dried and purified by a silica gel filtration (hexane:ethyl acetate = 1:9). After recrystallization from ethyl acetate, 54.6 g of white solid were obtained. The yield was 80% based on (+)-2-phenylacetyl-2-azabicyclo[2.2.1]hept-5-en-3-one employed.

¹H-NMR (CDCl₃): δ [ppm]
25 400 MHz
1.28 - 1.35 (1H);
1.40 (m, 1H);
2.38 - 2.45 (1H);
2.79 (m, 1H);
3.50 (AB syst., 2H);
3.52 (s, 3H);
30 4.98 (m, 1H);
5.75 (m, 2H);
5.98 (m, 1H).
7.20 - 7.38 (5H).

Example 10

35 Preparation of (+)-1-BOC-amino-4-hydroxymethyl-2-cyclopentene

15 g of crude (+)-1-amino-4-hydroxymethyl-2-

09992982-11401
FOI T T 2882660

09992982-111401

cyclopentene hydrochloride were dissolved in a mixture of 150 ml of water and 150 ml of dioxane at room temperature under nitrogen. The solution was adjusted to pH 14 with 1N NaOH, then a diethyl ether solution of tert-butyloxy-carbonyl fluoride (BOC-F, 20% excess) was added, and the mixture was stirred for a further 3 h at room temperature (BOC-F prepared as disclosed in Synthesis 1975, 599). The pH was adjusted to 2 with conc. HCl. After distillation of the organic solvents, 50 ml of water were added to the residue, and the mixture was extracted with 3x 100 ml of ethyl acetate. The combined organic phases were completely evaporated. The residue was crystallized in a mixture of 110 ml of diisopropyl ether and 80 ml of n-hexane. 11.95 g of title compound were obtained. The yield was 56%.

Melting point: 68 - 70°C

¹H-NMR (DMSO-d₆): δ [ppm]
400 MHz

1.18 (m, 1H);
1.38 (s, 9H);
2.26 (m, 1H);
2.65 (m, 1H);
3.33 (t, 2H);
4.45 (m, 1H);
4.55 (t, 1H);
5.62 (m, 1H);
5.79 (m, 1H);
6.73 (d, 1H).

Example 11

Preparation of (±)-1-propionylamino-4-hydroxymethyl-2-cyclopentene

16.6 g of (±)-2-propionyl-2-azabicyclo[2.2.1]-hept-5-en-3-one were dissolved in water (140 ml) and 2-butanol (66 ml) under nitrogen and cooled to -5°C. 3 g of sodium borohydride were added in portions over the course of 2 h. The mixture was stirred at 10°C for 2.5 h and then adjusted to pH 2.2 with a mixture of conc. hydrochloric acid and water (1/1). The solution was evaporated to 40 g and adjusted to pH 6.2 with 2N NaOH. The mixture

was extracted with 5x 50 ml of dichloromethane. The combined organic phases were completely evaporated, and the residue was recrystallized in toluene (150 ml). 11.1 g of title compound were obtained. The yield was 65%.

Melting point: 67 - 68°C

¹H-NMR (DMSO-d₆): δ [ppm] 0.96 (t, 3H);
400 MHz 1.16 (quint., 1H);
 2.04 (quart., 2H);
 2.26 (m, 1H);
 2.66 (m, 1H);
 3.34 (m, 2H);
 4.58 (t, 1H);
 4.72 (m, 1H);
 5.61 (m, 1H),
 5.84 (m, 1H),
 7.72 (d, 1H).

Example 12

Preparation of (±)-1-isobutyrylamino-4-hydroxymethyl-2-cyclopentene

9 g of (±)-2-isobutyryl-2-azabicyclo[2.2.1]hept-5-en-3-one were dissolved in water (32 ml) and 2-butanol (84 ml) under nitrogen and cooled to 0°C. 1.37 g of sodium borohydride were added in portions over the course of 3.5 h. The mixture was stirred for a further 3 h at 20°C, and it was then adjusted to pH 2.5 with a mixture of conc. hydrochloric acid and water (1/1) and then neutralized with 2N NaOH. The solution was evaporated to 40 g. The residue was extracted with 3x 80 ml of dichloromethane. The combined organic phases were completely evaporated. The resulting solid was crystallized in 25 ml of toluene. 6.8 g of title compound were obtained. The yield was 73.6%.

Melting point: 80 - 81°C

¹H-NMR (DMSO-d₆): δ [ppm] 0.98 (d, 6H);

400 MHz

1.16 (quint., 1H);
2.30 (m, 2H);
2.68 (m, 1H);
3.32 (t, 2H);
4.58 (t, 1H);
4.70 (m, 1H);
5.61 (m, 1H);
5.82 (m, 1H);
7.68 (d, 1H).

5

10 **Example 13**

Preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene using penicillin G acylases

Penicillin G acylase EC 3.5.1.11 from E.coli (Boehringer Mannheim) 165 U (units)/g or penicillin G acylase EC 3.5.1.11 from Bacillus megaterium was employed for the biotransformation.

For this, 50 mM sodium phosphate buffer (pH 5 - 9; 4 ml) was incubated with 1% by weight of non-racemic 1-phenylacetyl-amino-4-hydroxymethyl-2-cyclopentene and 400 mg of the appropriate penicillin G acylase at 37°C.

Samples were taken after defined time intervals and were analyzed by thin-layer chromatography (silica gel 60, butanol:water:glacial acetic acid = 3:1:1; detection with ninhydrin), gas chromatography (capillary column, HP-5, 5% phenylmethylsiloxane) or HPLC. The enzyme eliminated the phenylacetyl group with high activity and thereby liberated up to 40% of the corresponding amino alcohol. The free amino alcohol was obtained with a ee of 80%.

30 **Example 14**

Preparation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene using microorganisms

14.1 Sewage sludge (20%) from the ARA water treatment plant in Visp was incubated in the A + N medium (see Table 1) containing 0.5% by weight of 1-acetyl-, 1-propionyl-, 1-isobutyryl- or 1-butyrylamino-4-hydroxymethyl-2-cyclopentene at 37°C with shaking. The

09992982-11401

formation of (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopenten was followed by thin-layer chromatography.

5 1-3 transfers were carried out with 1% of these enrichments, and isolation took place on solid media (plate count agar in the medium of Table 1; 20 g/l). The microorganisms *Alcaligenes/Bordetella* FB 188 (DSM 1172), *Rhodococcus erythropolis* CB 101 (DSM 10686), *Gordona* sp. CB 100 (DSM 10687) and *Rhodococcus* sp. FB 387 (DSM 11291) were isolated in this way.

14.2 The microorganisms isolated in this way were cultivated in the medium (Table 1) containing 0.5% of 1-acetyl-, 1-propionyl-, 1-isobutyryl- or 1-butyryl-amino-4-hydroxymethyl-2-cyclopentene. They grew to an optical density (OD) of 2 to 3 in 24 to 36 hours. The cells obtained in this way were harvested in the late exponential phase of growth and were washed in 10 mM phosphate buffer.

20 The subsequent biotransformation was carried out in 50 mM phosphate buffer (pH 4.5-9) containing 1% by weight of 1-acetyl-, 1-isobutyryl- or 1-butyryl-amino-4-hydroxymethyl-2-cyclopentene. It was found by thin-layer chromatography that 50% of the substrate were hydrolyzed to (1R,4S)-1-amino-4-(hydroxymethyl)-2-cyclopentene. HPLC analyses revealed ee values between 80 and 93%.

25 When 1-butyrylamino-4-hydroxymethyl-2-cyclopentene was employed as substrate, the biotransformation rate was 0.14 (g/l/h/OD) for the strain DSM 10686 when cultivation took place on a A + N medium and 0.03 (g/l/h/OD) when cultivation took place on NYB (nutrient yeast broth) medium containing 1-butyryl-amino-4-hydroxymethyl-2-cyclopentene.

35 When the same conversion was carried out with the strain DSM 10687 at a substrate concentration (1-

0999982-11401
TOTTT-2862660

butyrylamino-4-hydroxymethyl-2-cyclopentene) of 200 mM, the biotransformation rate was 0.161 (g/l/h/OD).

Table 1 A + N medium

5	MgCl ₂	0.4 g/l
	CaCl ₂	0.014 g/l
	FeCl ₃	0.8 mg/l
	Na ₂ SO ₄	0.1 g/l
	KH ₂ PO ₄	1 g/l
10	Na ₂ HPO ₄	2.5 g/l
	NaCl	3 g/l
	Vitamin solution	1 ml/l
	Trace element solution	1 ml/l
	pH 7.5	

- 15 14.3 *Rhodococcus erythropolis* DSM 10686 was cultured in minimal medium (cf. Table 2) with ammonium acetate (3 g/l) as carbon and nitrogen source in a 6 l fermenter at 30°C to a cell density of OD 650 > 25. During cell growth, 50% acetic acid was added continuously as additional C source. In order to induce the enzymatic activity, 60 g of (+/-)-1-acetylamino-4-hydroxymethyl-2-cyclopentene were then added, and incubation was continued for some hours. Finally, a further 40 g of (+/-)-1-acetylamino-4-hydroxymethyl-2-cyclopentene were added, and incubation was then carried out for a further 10 hours. The progress of the biotransformation was followed on-line by HPLC. When an analytical yield of 40%, based on the racemic substrate employed, and a ee of 85% were reached, fermentation was stopped by adding acid.

Table 2

Media composition

	Component	Concentration
	Yeast extract	0.5 g/l
35	Peptone M66	0.5 g/l
	KH ₂ PO ₄	4.0 g/l
	Na ₂ HPO ₄ ·2H ₂ O	0.5 g/l
	K ₂ SO ₄	2.0 g/l

09992982-111401

	NH ₄ acetate	3.0 g/l
	CaCl ₂	0.2 g/l
	MgCl ₂ ·6H ₂ O	1.0 g/l
	Trac element solution	1.5 ml/l
5	(see below)	
	PPG (polypropylene glycol)	0.1 g/l
	Trace element solution	
	KOH	15.1 g/l
	EDTA·Na ₂ ·2H ₂ O	100.0 g/l
10	ZnSO ₄ ·7H ₂ O	9.0 g/l
	MnCl ₂ ·4H ₂ O	4.0 g/l
	H ₃ BO ₃	2.7 g/l
	CoCl ₂ ·6H ₂ O	1.8 g/l
	CuCl ₂ ·2H ₂ O	1.5 g/l
15	NiCl ₂ ·6H ₂ O	0.18 g/l
	Na ₂ MoO ₄ ·2H ₂ O	0.27 g/l

- 14.4 In analogy to Example 14.3, the microorganisms *Arthrobacter* sp. HSZ 5 (DSM 10328, *Rhodococcus* sp. FB387 (DSM 11291), *Alcaligenes xylosoxydans* ssp. *denitrificans* HSZ 17 (DSM 10329), *Agrobacterium/Rhizobium* HSZ 30, *Bacillus simplex* K2 and *Pseudomonas putida* K32 were cultured on sodium acetate in the medium (Table 1) with and without 1-acetyl-, 1-propionyl-, 1-isobutyryl- or 1-butyryl-amino-4-hydroxymethyl-2-cyclopentene, abbreviated to amino alcohols hereinafter.

The following results were obtained with exponential cells cultured without amino alcohols (HPLC analysis):

30	Strain	Rate [mmol/OD.h]	ee/conversion [%]
	HSZ 5 (DSM 10328)	0.05	88.7/16
	HSZ 17 (DSM 10329)	0.005	95/23
	K32	0.05	54/1
	CB101 (DSM 10686)	0.1	84/39

104TTT 2862660

The strains K2 and K17 were cultured, harvested and subjected to a 60-hour biotransformation.

	Strain	Rate [mmol/OD.h]	ee/conversion [%]
	K2	-	92/10
5	HSZ 30	-	93/3.5

Exponential and stationary cells were harvested from all the batches and employed as quiescent cells for the biotransformation. There was no observable difference, from the TLC analysis, in the initial rate of cells induced with amino alcohol or not induced.

Example 15

Purification of the N-acetylamino-alcohol hydrolase from *Rhodococcus erythropolis* CB101 (DSM 10686)

15 The enzyme was purified as described below until there was only one protein band in the SDS-PAGE (Pharmacia Phast gel, 10-15% gradient) at a molecular weight of 50 kD.

20 Cells of *Rhodococcus erythropolis* CB101 (DSM 10686) were washed in 50 mM tris buffer (pH 6.2) and concentrated to an optical density $OD_{650\text{ nm}}$ of 190. After addition of phenylmethanesulphonyl fluoride (PMSF) to a final concentration of 1 mM and DNase, the cells were treated with a French press in order to obtain a crude
25 extract. Centrifugation resulted in 200 ml of a cell-free extract with a protein concentration of 4.8 mg ml^{-1} .

960 mg of the cell-free extract were loaded onto a HiLoad 26/10 Q-Sepharose ion exchange chromatography column (Pharmacia) which had been equilibrated with a
30 50 mM tris buffer (pH 8.0) containing 1 mM dithiothreitol (DTT).

After the column had been washed with the same buffer, the proteins were eluted with a linear buffer gradient (1500 ml; gradient: 50 mM tris buffer (pH 8.0)
35 containing 1 mM DTT - 50 mM tris buffer (pH 7.0) containing 1 mM DTT and 1 M NaCl). The enzym eluted from the column between 370 and 430 mM NaCl and at a pH of 7.6.

09992982-11401
FOHFF-286660

The active fractions were collected and concentrated to 9 ml. The protein content was 41 mg.

For further purification, the protein solution was loaded onto a HiLoad 26/60 Superdex 75 gel filtration chromatography column (Pharmacia) which had been equilibrated with a 50 mM Tris buffer containing 50 mM NaCl and 1 mM DTT. The active fractions were combined and had a total protein content of 10.9 mg.

This protein solution was loaded onto a Mono Q HR5/5 column (Pharmacia) which had been equilibrated with 50 mM Tris buffer (pH 8.5) containing 1 mM DTT. The proteins were eluted with a linear gradient (40 ml) of 50 mM Tris buffer (pH 8.5) containing 1 mM DTT - 50 mM Tris buffer (pH 8.5) containing 1 mM DTT and 1 M NaCl. The enzyme eluted between 390 mM NaCl and 440 mM NaCl. The active fractions contained 1.4 mg of protein.

In the last purification step, the same column was used, equilibrated with the same buffer. The elution gradient used was the same buffer with 0 - 500 mM NaCl and pH 7.0 - 8.5. It was possible in this way to isolate 430 µg of pure enzyme.

The N-terminal sequence of the enzyme was determined directly from the protein blot. A sequence of the following 20 amino acids was obtained: Thr-Glu-Gln-Asn-Leu-His-Trp-Leu-Ser-Ala-Thr-Glu-Met-Ala-Ala-Ser-Val-Ala-Ser-Asn.

This sequence showed no homology with known proteins.

Example 16

Enzyme characterization

The enzyme characterization was carried out both with purified enzyme and with cell-free extract which had been desalted using a Sephadex G-25 column (PD-10, Pharmacia).

The protein concentration in the cell-free extract was 7.3 mg ml⁻¹ and the protein concentration of the purified enzyme was 135 µg ml⁻¹. PMSF was not added to the cell-free extract.

09992982-11401

16.1 K_m determination

The K_m determination was carried out in a cell-free extract. The K_m for the reaction at pH 7.0 and at a temperature of 30°C was 22.5 mM for the substrate 1-acetylamino-4-hydroxymethyl-2-cyclopentene.

16.2 pH optimum

The pH optimum for the hydrolysis of 1-acetylamino-4-hydroxymethyl-2-cyclopentene (25 mM) was determined with the purified enzyme and in cell-free extract in a pH range of pH 6.2-9.0 in the following buffer solutions.

Tris buffer 100 mM pH 9.0; 8.5; 8.0; 7.5; 7.0

Citrate/phosphate buffer 100 mM pH 7.0; 6.55; 6.2

The activity was measured for 24 h.

The pH optimum for the reaction was between pH 7.0 and pH 7.5 for production of the 1R,4S and the 1S,4R enantiomer.

The pH optimum for the activity in the cell-free extract was at pH 7.0. The selectivity was, however, better between pH 6.0 and pH 7.0.

Figure 1 shows the activity of the N-acetylamino-alcohol hydrolase (cell-free extract) from *Rhodococcus erythropolis* CB 101 (DSM 10686) as a function of the pH.

- 16.3 The temperature optimum for the reaction indicated in Example 16.2 was between 25 and 30°C.

Figure 2 shows the activity of the N-acetylamino-alcohol hydrolase (cell-free extract) from *Rhodococcus erythropolis* CB 101 (DSM 10686) as a function of the temperature.

09992982-11401

09194626SeqList.txt

<110> Bernegger-Egli, Christine
Birch, Owen M.
Bossurd, Pierre
Brieden, Walter
Brux, Frank
Burgdorf, Knut
Duc, Laurent
Etter, Kay-Sarah
Guggisberg, Ives
Sauter, Martin
Urban, Eva

<120> PROCESS FOR THE PREPARATION OF AN AMINO
ALCOHOL

<130> A32092 PCT-USA

<140> 09/194,626

<141> 1999-05-21

<150> PCT/EP97/02838

<151> 1997-05-30

<160> 1

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 20

<212> PRT

<213> Rhodococcus erythropolis

09992982-111401

09194626SeqList.txt

<400> 1
Thr Glu Gln Asn Leu His Trp Leu Ser Ala Thr Glu Met Ala Ala Ser
1 5 10 15
Val Ala Ser Asn
20

09992982.111401

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISM
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Lonza AG
Walliser Werk

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Lonza AG Walliser Werk Address: CH-3930 Visp	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 11291 Date of the deposit or the transfer ¹ : 1996-10-08
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 1996-10-08 ¹ . On that date, the said microorganism was (X) ² viable () ² no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ³	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>V. Wicks</i> Date: 1996-11-22

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- ² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
- ³ Mark with a cross the applicable box.
- ⁴ Fill in if the information has been requested and if the results of the test were negative.

T041111-28626650

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Lonza AG
Walliser Werk

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: FB 387	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 11291
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1996-10-08 (Date of the original deposit).	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Wetz</i> Date: 1996-11-22

Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: LONZA AG Address: CH-3930 Visp		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10687 Date of the deposit or the transfer: 1996-05-20	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 1996-05-20. On that date, the said microorganism was <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Wehls</i> Date: 1996-05-21	

Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

Mark with a cross the applicable box.

Fill in if the information has been requested and if the results of the test were negative.

09992982-111401

- 39 -
BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: LONZA AG Address: CH-3930 Visp	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10686 Date of the deposit or the transfer: 1996-05-20
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 1996-05-20. On that date, the said microorganism was <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Wechs</i> Date: 1996-05-21

- * Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- * In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
- * Mark with a cross the applicable box.
- * Fill in if the information has been requested and if the results of the test were negative.

0992982 1144
F04T 2862660


BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: BEC005	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10686
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
<p>The microorganism identified under I. above was accompanied by:</p> <p>() a scientific description () a proposed taxonomic designation</p> <p>(Mark with a cross where applicable).</p>	
III. RECEIPT AND ACCEPTANCE	
<p>This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1996-05-20 (Date of the original deposit)¹.</p>	
IV. RECEIPT OF REQUEST FOR CONVERSION	
<p>The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).</p>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s).  Date: 1996-05-21

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG
Forschung Biotechnologie
Lonzastr.

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM

Identification reference given by the DEPOSITOR:

HSZ 17

Accession number given by the
INTERNATIONAL DEPOSITARY AUTHORITY:

DSM 10329

II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION

The microorganism identified under I. above was accompanied by:

☒ (X) a scientific description☒ (X) a proposed taxonomic designation

(Mark with a cross where applicable).

III. RECEIPT AND ACCEPTANCE

This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1995-11-06
(Date of the original deposit)¹.

IV. RECEIPT OF REQUEST FOR CONVERSION

The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit)
and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request
for conversion).

V. INTERNATIONAL DEPOSITARY AUTHORITY

Name: DSM-DEUTSCHE SAMMLUNG VON
MIKROORGANISMEN UND ZELLKULTUREN GmbHAddress: Mascheroder Weg 1b
D-38124 BraunschweigSignature(s) of person(s) having the power to represent the
International Depositary Authority or of authorized official(s):

Date: 1995-11-14

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

09992982-11401

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG
Forschung Biotechnologie
Lonzastr.

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
<p>Name: LONZA AG Forschung Biotechnologie Address: Lonzastr. CH-3930 Visp</p>	<p>Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10329</p> <p>Date of the deposit or the transfer: 1995-11-06</p>
III. VIABILITY STATEMENT	
<p>The viability of the microorganism identified under II above was tested on 1995-11-06. On that date, the said microorganism was</p> <p>(X) viable () no longer viable</p>	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
<p>Name: DSM-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH</p> <p>Address: Mascheroder Weg 1b D-38124 Braunschweig</p>	<p>Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):</p> <p><i>Dejmur</i></p> <p>Date: 1995-11-14</p>

1. Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
2. In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
3. Mark with a cross the applicable box.
4. Fill in if the information has been requested and if the results of the test were negative.

T04T " 2862660


BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG
Forschung Biotechnologie
Lonzastr.

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: HSZ 5	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10328
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1995-11-06 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSM-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 1995-11-14

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE


INTERNATIONAL FORM

LONZA AG
Forschung Biotechnologie
Lonzastr.

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: LONZA AG Forschung Biotechnologie Address: Lonzastr. CH-3930 Visp		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10328 Date of the deposit or the transfer ¹ : 1995-11-06	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 1995-11-06. On that date, the said microorganism was <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ²			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSM-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 1995-11-14	

¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

³ Mark with a cross the applicable box.

⁴ Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL
COGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Lonza AG
Walliser Werk

CH-3930 Visp

VIABILITY STATEMENT

issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Lonza AG Walliser Werk Address: CH-3930 Visp	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 11172 Date of the deposit or the transfer ¹ : 1996-09-20
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 1996-09-20 ¹ . On that date, the said microorganism was (X) ² viable () ³ no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Wechs</i> Date: 1996-11-22

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
- ² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
- ³ Mark with a cross the applicable box.
- ⁴ Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL
COGNITION OF THE DEPOSIT OF MICROORGANISM
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

Lonza AG
Walliser Werk

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: FB 188	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 11172
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I. above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable).	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1996-09-20 (Date of the original deposit) ¹ .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Wetz</i> Date: 1996-11-22

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL
COGNITION OF THE DEPOSIT OF MICROORGANISM
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

LONZA AG

CH-3930 Visp

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: BEC006	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 10687
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
<p>The microorganism identified under I. above was accompanied by:</p> <p>() a scientific description () a proposed taxonomic designation</p> <p>(Mark with a cross where applicable).</p>	
III. RECEIPT AND ACCEPTANCE	
<p>This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 1996-05-20 (Date of the original deposit)¹.</p>	
IV. RECEIPT OF REQUEST FOR CONVERSION	
<p>The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).</p>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s): <i>U. Weiler</i> Date: 1996-05-21

¹ Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

09992982-111401